Статья
СВЯЗЬ БИОЛОГИЧЕСКИХ МАРКЕРОВ С ЭХОКАРДИОГРАФИЧЕСКИМИ ПОКАЗАТЕЛЯМИ У БОЛЬНЫХ ИНФАРКТОМ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST И СОХРАННОЙ СИСТОЛИЧЕСКОЙ ФУНКЦИЕЙ ЛЕВОГО ЖЕЛУДОЧКА
Цель. Сопоставление динамики концентраций биологических маркеров с ЭхоКГ показателями у больных ИМ с подъемом сегмента ST (ИМпST) и сохранной функцией ЛЖ в периоде госпитализации. Материалы и методы. Последовательно включены 100 пациентов с диагнозом ИМпST с ФВ ЛЖ >40%. Всем пациентам проведена реваскуляризация симптомзависимой артерии. Эхокардиографическое исследование проводилось всем пациентам на 1-е и 10-12-е сутки госпитализации. У всех пациентов при поступлении в стационар и в динамике на 10-12-е сутки от начала заболевания проводилось определение концентраций в сыворотке крови маркеров: матриксных металлопротеиназ-1, 2 и 3 (ММП), тканевого ингибитора матриксной металлопро-теиназы-1 (ТИМП-1), галектина-3; N-терминального мозгового натрийуретического пропептида (NT-proBNP); растворимого белка семейства рецепторов ИЛ-1 (sST2). Результаты. Выявлено увеличение (р
1. Johansson S/, Rosengren A/, Young K/, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovascular Disorders. 2017; 17 (1). DOI: 10.1186/s12872-017-0482-9
2. Оганов Р.Г., Погосова Г.В. Современные стратегии профилактики и лечения ССЗ. Кардиология. 2007; 47 (12): 1-10.
3. Рагино Ю.И., Чернявский А.М., Полонская Я.В., Волков А.М., Каштанова Е.В., Цымбал С. Ю. Воспалительно-деструктивные биомаркеры нестабильности атеросклеротических бляшек: исследования сосудистой стенки и крови. Кардиология. 2012; 52 (5): 37-41.
4. Von Lueder T.G., Wang B.H., Kompa A.R., Huang L., Webb R., Jordaan P. et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circulation: Heart Failure. 2015; 8 (1): 71-8. DOI: 10.1161/CIRCHEARTFAILURE.114.001785
5. French B.A., Kramer C.M. Mechanisms of postinfarct left ventricular remodeling. Drug Discovery Today: Disease Mechanisms. 2007; 4 (3): 185-96. DOI: 10.1016/j. ddmec. 2007.12.006
6. Galli A., Lombardi F. Postinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart Failure. Cardiology Research and Practice. 2016; 2016: 1-12. DOI: 10.1155/2016/2579832
7. Carrick D., Haig C., Rauhalammi S., Ahmed N., Mordi I., McEntegart M. et al. Pathophysiology of LV Remodeling in Survivors of STEMI. JACC: Cardiovascular Imaging. 2015; 8 (7): 779-89. DOI: 10.1016/j.jcmg. 2015.03.007
8. Marshall R.P., Simpson J.K., Lukey P.T. Strategies for biomarker discovery in fibrotic disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2013; 1832 (7): 1079-87. DOI: 10.1016/j.bbadis. 2013.01.018
9. Zile M.R., Baicu C.F., Ikonomidis J.S., Stroud R.E., Nietert P.J., Bradshaw A.D. et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and ti-tin. Circulation. 2015; 131 (14): 1247-59. DOI: 10.1161/CIRCU-LATIONAHA. 114.013215
10. Rogers F.J., Gundala T., Ramos J.E., Serajian A. Heart Failure With Preserved Ejection Fraction. The Journal of the American Osteopathic Association. 2015; 115 (7): 432. DOI: 10.7556 /jaoa.2015.089
11. Prevalence, clinical characteristics and outcomes of HF with preserved versus reduced ejection fraction. British Journal of Cardiology. 2016; DOI: 10.5837/bjc.2016.005
12. Chu J.W., Jones G.T., Tarr G.P., Phillips L.V., Wilkins G.T., van Rij AM et al. Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function. International Journal of Cardiology. 2013; 167 (4): 1242-6. DOI: 10.1016/j.ij-card. 2012.03.147
13. O’Donoghue M.L., Morrow D.A., Cannon C.P., Jarolim P., Desai N.R., Sherwood MW et al. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2016; 5 (5). DOI: 10.1161/JAHA.115.002586
14. Bartunek J., Delrue L., Van Durme F., Muller O., Casselman F., De Wiest B. et al. Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic Load. Journal of the American College of Cardiology. 2008; 52 (25): 2166-74. DOI: 10.1016/j.jacc.2008.09.027
15. Wang Y.-C., Yu C.-C., Chiu F.-C., Tsai C.-T., Lai L.-P., Hwang J.-J. et al. Soluble ST2 as a Biomarker for Detecting Stable Heart Failure With a Normal Ejection Fraction in Hypertensive Patients. Journal of Cardiac Failure. 2013; 19 (3): 163-8. DOI: 10.1016/j.cardfail. 2013.01.010
16. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016; 37 (27): 2129-200. DOI: 10.1093/eurheartj/ehw128
17. Huttin O., Coiro S., Selton-Suty C., Juillière Y., Donal E., Magne J. et al. Prediction of Left Ventricular Remodeling after a Myocardial Infarction: Role of Myocardial Deformation: A Systematic Review and Meta-Analysis. Rouet P, editor. PLOS ONE. 2016; 11 (12): e0168349. DOI: 10.1371/journal.pone.0168349
18. Reis Filho J.R. de A.R., Cardoso J.N., Cardoso C.M. dos R., Pereira-Barretto A.C. Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure. Arquivos Brasileiros de Cardiologia. 2015; DOI: 10.5935/abc.20150025
19. Zouein F.A., Zgheib C., Liechty K.W., Booz G.W. Post-Infarct Biomaterials, Left Ventricular Remodeling, and Heart Failure: Is Good Good Enough?: acellular biopolymers to limit cardiac remodeling. Congestive Heart Failure. 2012; 18 (5): 284-90. DOI: 10.1111/j.1751-7133.2012.00298.
20. Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP): review article. Cardiovascular Journal Of Africa. 2013; 24 (7): 286-9. DOI: 10.5830/CVJA-2013-055
21. Vardeny O., Miller R., Solomon S.D. Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Fail- 36. ure. JACC: Heart Failure. 2014; 2 (6): 663-70. DOI: 10.1016/j.jchf. 2014.09.001
22. Johnson J. Matrix metalloproteinases and their inhibitors in cardiovascular pathologies: current knowledge and clinical potential. Metalloproteinases In Medicine. 2014; 21. DOI: 10.2147/MNM.S50999
23. Orn S., Manhenke C., Squire I.B., Ng L, Anand I., Dickstein K. Plasma MMP-2, MMP-9 and N-BNP in Long-Term Survivors Following Complicated Myocardial Infarction: Relation to Cardiac Magnetic Resonance Imaging Measures of Left Ventricular Structure and Function. Journal of Cardiac Failure. 2007; 13 (10): 843-9. DOI: 10.1016/j.cardfail. 2007.07.006
24. Jordan A., Roldan V., Garcia M., Monmeneu J., de Burgos F.G., Lip G.Y.H. et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. Journal of Internal Medicine. 2007; 262 (3): 385-92. DOI: 10.1111/j.1365-2796.2007.01823.x
25. Creemers E.E.J.M., Davis J.N., Parkhurst A.M., Leenders P., Dowdy K.B., Hapke E. et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. American Journal of Physiology-Heart and Circulatory Physiology. 2003; 284 (1): H364-71. DOI: 10.1152/ajpheart.00511.2002
26. Kelly D., Khan S.Q., Thompson M., Cockerill G., Ng L.L., Samani N. et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. European Heart Journal. 2008; 29 (17): 2116-24. DOI: 10.1093/eurheartj/ehn315
27. Sundstrom J. Relations of Plasma Matrix Metalloproteinase-9 to Clinical Cardiovascular Risk Factors and Echocardiogra-phic Left Ventricular Measures: The Framingham Heart Study. Circulation. 2004; 109 (23): 2850-6. DOI: 10.1161/01.CIR. 0000129318.79570.84
28. Ohtsuka T., Nishimura K., Kurata A., Ogimoto A., Okayama H., Higaki J. Serum Matrix Metalloproteinase-3 as a Novel Marker for Risk Stratification of Patients With Nonischemic Dilated Cardiomyopathy. Journal of Cardiac Failure. 2007; 13 (9): 752-8. DOI: 10.1016/j.cardfail.2007.06.730
29. Ho J.E., Liu C., Lyass A., Courchesne P., Pencina M.J., Vasan R.S. et al. Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. Journal of the American College of Cardiology. 2012; 60 (14): 1249-56. DOI: 10.1016/j.jacc. 2012.04.053
30. Di Tano G., Caretta G., De Maria R., Parolini M., Bassi L., Testa S. et al. Galectin-3 predicts left ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention. Heart. 2017; 103 (1): 71-7. DOI: 10.1136/heartjnl-2016-309673
31. Felker G.M., Fiuzat M., Shaw L.K., Clare R., Whellan D.J., Bettari L. et al. Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study. Circulation: Heart Failure. 2012; 5 (1): 72-8. DOI: 10.1161/CIRCHEARTFAILURE. 111.963637
32. Gonzalez A., Lopez B., Ravassa S., Beaumont J., Arias T., Hermida N. et al. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovascular Research. 2008; 81 (3): 509-18. DOI: 10.1093/cvr/cvn235
33. Cardiac biomarkers: expert advice for clinicians. 1st ed. Maisel AS, editor. - New Delhi: Jaypee Bros. Medical Pub; 2012. 239 p. ISBN: 978-93-5025-564-3
34. Zhang., Zhang X., Mi Y., Liu J. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin Med J. 2013; 126 (19): 3628-31.
35. Santhanakrishnan R., Chong J.P.C., Ng T.P., Ling L.H., Sim D., Toh G. Leong K et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. European Journal of Heart Failure. 2012; 14 (12): 1338-47. DOI: 10.1093/eurjhf/hfs130
36. Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A. et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006; 355 (3): 260-9. DOI: 10.1056/NEJMoa051530
37. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine. 2006; 355 (3): 251-9. DOI: 10.1056/NEJMoa052256
38. Meluzin J., Tomandl J. Can Biomarkers Help to Diagnose Early Heart Failure with Preserved Ejection Fraction? Disease Markers. 2015; 2015: 1-9. DOI: 10.1155/2015/426045
39. Paulus W.J., Tschöpe C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal. 2007; 28 (20): 2539-50. DOI: 10.1093/eurheartj/ehm037